Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults

The immunogenicity of the candidate tuberculosis (TB) vaccine MVA85A may be enhanced by aerosol delivery. Intradermal administration was shown to be safe in adults with latent TB infection (LTBI), but data are lacking for aerosol-delivered candidate TB vaccines in this population. We carried out a P...

Повний опис

Бібліографічні деталі
Автори:	Riste, M, Marshall, JL, Satti, I, Harris, SA, Wilkie, M, Lopez Ramon, R, Wright, D, Wittenberg, RE, Vermaak, S, Powell Doherty, R, Lawrie, A, Conlon, CP, Cosgrove, C, Gleeson, F, Lipman, M, Moss, P, Perrin, F, Dedicoat, M, Bettinson, H, McShane, H
Формат:	Journal article
Мова:	English
Опубліковано:	MDPI 2021

Схожі ресурси

Phase I Trial Evaluating the Safety and Immunogenicity of Candidate TB Vaccine MVA85A, Delivered by Aerosol to Healthy <em>M.tb</em>-Infected Adults
за авторством: Michael Riste, та інші
Опубліковано: (2021-04-01)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
за авторством: Thomas, Z, та інші
Опубліковано: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
за авторством: Tameris, M, та інші
Опубліковано: (2014)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
за авторством: Tameris, M, та інші
Опубліковано: (2014)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
за авторством: Mcshane, H
Опубліковано: (2008)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial
за авторством: Manjaly Thomas, Z, та інші
Опубліковано: (2019)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
за авторством: Rowland, R, та інші
Опубліковано: (2012)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
за авторством: Michele Tameris, та інші
Опубліковано: (2014-01-01)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
за авторством: Harris, S, та інші
Опубліковано: (2011)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
за авторством: Meyer, J, та інші
Опубліковано: (2013)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
за авторством: Meyer, J, та інші
Опубліковано: (2013)

Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial.
за авторством: Zita-Rose Manjaly Thomas, та інші
Опубліковано: (2019-04-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial.
за авторством: Anne Wajja, та інші
Опубліковано: (2017-05-01)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
за авторством: Wajja, A, та інші
Опубліковано: (2017)

Phase I/II clinical trial of MVA85A in individuals with latent tuberculosis: The first subunit TB vaccine in clinical trial
за авторством: Sander, C, та інші
Опубліковано: (2005)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
за авторством: Minassian, A, та інші
Опубліковано: (2011)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
за авторством: Harris, S, та інші
Опубліковано: (2013)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
за авторством: Odutola, A, та інші
Опубліковано: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
за авторством: Odutola, A, та інші
Опубліковано: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
за авторством: Dieye, T, та інші
Опубліковано: (2013)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
за авторством: Wilkie, M, та інші
Опубліковано: (2019)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
за авторством: Whelan, K, та інші
Опубліковано: (2009)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
за авторством: Pathan, A, та інші
Опубліковано: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
за авторством: Pathan, A, та інші
Опубліковано: (2012)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
за авторством: Owiafe, P, та інші
Опубліковано: (2012)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naïve subjects gives comparable immunogenicity to one dose in ART+ subjects.
за авторством: Tandakha N Dieye, та інші
Опубліковано: (2013-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
за авторством: Kathryn T. Whelan, та інші
Опубліковано: (2011-01-01)

TB vaccine development: where are we and why is it so difficult?
за авторством: Wilkie, M, та інші
Опубліковано: (2014)

Correction: Two Doses of Candidate TB Vaccine MVA85A in Antiretroviral Therapy (ART) Naïve Subjects Gives Comparable Immunogenicity to One Dose in ART+ Subjects.
за авторством: Tandakha N. Dieye, та інші
Опубліковано: (2013-01-01)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
за авторством: Minhinnick, A, та інші
Опубліковано: (2016)

Diagnosis of extrapulmonary TB: Experience with the Xpert MTB/Rif assay
за авторством: C.N. Govind, та інші
Опубліковано: (2014-04-01)

Evaluation of Xpert MTB/RIF assay for the diagnosis of paediatric TB
за авторством: F. Ismail, та інші
Опубліковано: (2014-04-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Опубліковано: (2011-01-01)

Diagnostic performance of GeneXpert MTB/RIF in detecting MTB in smear-negative presumptive TB patients
за авторством: Raksha Rimal, та інші
Опубліковано: (2022-04-01)

Impact of introduction of Xpert MTB/RIF test on tuberculosis (TB) diagnosis in a city with high TB incidence in Brazil.
за авторством: Giovana Rodrigues Pereira, та інші
Опубліковано: (2018-01-01)

Enhancing TB case detection: experience in offering upfront Xpert MTB/RIF testing to pediatric presumptive TB and DR TB cases for early rapid diagnosis of drug sensitive and drug resistant TB.
за авторством: Neeraj Raizada, та інші
Опубліковано: (2014-01-01)

Effects of MVA85A vaccine on tuberculosis challenge in animals: systematic review
за авторством: Mcshane, H, та інші
Опубліковано: (2016)

TB or not TB?
за авторством: Andrew Pirotte, та інші
Опубліковано: (2024-04-01)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
за авторством: Satti, I, та інші
Опубліковано: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
за авторством: Satti, I, та інші
Опубліковано: (2014)